Vaginal Radical Trachelectomy (n=34) Radical Hysterectomy (n=9) (Chemo)radiotherapy (n=32) Total (n=75)
Age, median (range) 31 (25-37) 30 (25-37) 29 (24-36) 31 (24-37)
BMI, median (range) 22.5 (18.0-36.7) 21.2 (17.3-36.7) 22.0 (18-33.3) 22.1 (17.3-36.7)
Parity
Nulliparous 27 (79.4%) 7 (77.8%) 28 (87.5) 62 (82.7%)
Parous 7 (20.6%) 2 (22.2%) 4 (12.5%) 13 (17.3%)
Stage
IA2 1 (11.1%) 1 (1.3%)
IB1 30 (88.2%) 3 (33.3%) 33 (44.0%)
IB2 3 (8.8%) 4 (44.4%) 2 (6.3%) 9 (12.0%)
IB3 1 (2.9%) 3 (9.4%) 4 (5.3%)
≥ II 1 (11.1%) 27 (84.8%) 28 (37.3%)
Grade
I 7 (20.6%) 2 (22.2%) 4 (12.5%) 13 (17.3%)
II 18 (52.9%) 5 (55.6%) 16 (50.0%) 39 (52.0%)
III 9 (26.5%) 2 (22.2%) 12 (37.5%) 23 (30.7%)
Histology
Squamous cell carcinoma 27 (79.4%) 5 (55.6%) 22 (68..8%) 54 (71.1%)
Adenocarcinoma 6 (17.6%) 4 (44.4%) 7 (21.9%) 17 (22.7%)
Adenosquamous carcinoma 1 (2.9%) 2 (6.3%) 3 (4.0%)
Neuroendocrine 1 (3.1%) 1 (1.3%)
Median tumor size in mm (range) 9.0 (6.0-40.0)* 20.0 (7.0-35.0) 40.0 (20-73) 20.0 (6.0-73)
LVSI
No 21 (61.8%) 6 (66.7%) 18 (56.3%) 45 (60.0%)
Yes 13 (38.2%) 3 (33.3%) 13 (40.6%) 30 (40.0%)
Lymph node metastasis
No 34 (100%) 9 (100%) 9 (28.1%) 52 (69.3%)
Yes 0 (0%) 0 (0%) 23 (71.9%) 23 (30.7%)
Neoadjuvant chemotherapy 1 (2.9%) 2 (2.7%)
Follow-up in months 55 (1-132) 25 (8-64) 37 (12-134) 49 (1-134)
Recurrence - - 5 (15.6%) 5 (6.7%)
Deceased - - 5 (15.6%) 5 (6.7%)
a according to the FIGO 2018 staging a according to the FIGO 2018 staging a according to the FIGO 2018 staging a according to the FIGO 2018 staging a according to the FIGO 2018 staging